HLB Chairman Kim Tae-han says issues with rivoceranib production facility resolved, confident of FDA approval
Predicted impact: Low· Actual: −4.6% vs sector, volume 0.3× normal (5 trading days)
Management reiterates FDA approval confidence; the same expectation was already stated this period.